Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-based Therapies vs Standard Triple Therapy for First-line H. Pylori Eradication
NCT06349486Recruiting
- Sponsor
- Kaohsiung Medical University
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vonoprazan in Helicobacter pylori infection (3 arms), sponsored by Kaohsiung Medical University. Primary endpoint: Eradication rate of Helicobacter pylori. Started Nov 2023; status: recruiting.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06349486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06349486.